PXMD RSI Chart
Last 7 days
14.3%
Last 30 days
-70%
Last 90 days
-63.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 12, 2024 | weisman howard j. | sold (taxes) | -2,019 | 0.69 | -2,927 | chief executive officer |
Mar 12, 2024 | coelho john f | sold (taxes) | -142 | 0.69 | -207 | - |
Mar 12, 2024 | casamento charles j | sold (taxes) | -684 | 0.69 | -992 | - |
Mar 12, 2024 | hough david w. | sold (taxes) | -1,001 | 0.69 | -1,452 | chief medical officer |
Mar 12, 2024 | sheldon stephen | sold (taxes) | -2,315 | 0.69 | -3,356 | cfo and coo |
Mar 12, 2024 | larochelle karen | sold (taxes) | -416 | 0.69 | -604 | - |
Mar 12, 2024 | rome zachary | sold (taxes) | -3,383 | 0.69 | -4,904 | - |
Feb 21, 2024 | hough david w. | sold (taxes) | -191 | 0.659 | -291 | chief medical officer |
Feb 21, 2024 | sheldon stephen | sold (taxes) | -160 | 0.659 | -243 | cfo and coo |
Jan 29, 2024 | casamento charles j | sold (taxes) | -73.72 | 0.76 | -97.00 | - |
Which funds bought or sold PXMD recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -21,176 | - | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | added | 47.93 | -29.00 | 8,410 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 4.09 | -1,525 | 3,582 | -% |
May 14, 2024 | Clearstead Advisors, LLC | reduced | -99.96 | -1,698 | 1.00 | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -372 | - | -% |
May 10, 2024 | JPMORGAN CHASE & CO | sold off | -100 | -4,314 | - | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | added | 3.45 | -13.00 | 30.00 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 1,400 | 13.00 | 15.00 | -% |
May 08, 2024 | Souders Financial Advisors | new | - | 20,400 | 20,400 | -% |
May 07, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | new | - | 13,306 | 13,306 | -% |
Unveiling PaxMedica, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to PaxMedica, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
PaxMedica, Inc. News
Balance Sheet | ||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 |
Assets | -49.1% | 2,893 | 5,680 | 3,234 | 5,144 | 4,752 | 2,204 | 5,980 | 556 | 603 | 649 | 1,124 |
Current Assets | -49.1% | 2,893 | 5,680 | 3,234 | 5,144 | 4,752 | 2,204 | 5,980 | 9.00 | - | 444 | 1,124 |
Cash Equivalents | -65.5% | 1,627 | 4,711 | 1,153 | 3,070 | 3,986 | 1,902 | 5,563 | 9.00 | 49.00 | 444 | 1,124 |
Liabilities | -25.8% | 1,703 | 2,295 | 3,770 | 2,879 | 2,220 | 2,096 | 3,591 | 8,453 | 9,605 | 10,758 | 5,752 |
Current Liabilities | -33.0% | 1,203 | 1,795 | 3,270 | 2,425 | 1,799 | 2,096 | 3,591 | 8,453 | - | 10,758 | 5,752 |
Shareholder's Equity | -64.8% | 1,190 | 3,385 | - | 2,265 | 2,533 | 109 | 2,388 | - | - | - | - |
Retained Earnings | -7.2% | -55,722 | -52,000 | -46,109 | -41,060 | -37,600 | -33,740 | -28,500 | -17,055 | - | -18,938 | -8,709 |
Additional Paid-In Capital | 2.7% | 56,912 | 55,414 | 45,572 | 43,324 | 40,105 | 33,849 | 30,906 | 9,158 | - | 8,828 | 4,080 |
Shares Outstanding | 0.9% | 7,466 | 7,401 | 1,074 | 904 | 819 | 708 | 452 | 407 | 407 | 407 | 340 |
Float | - | - | - | - | 4,100 | - | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Cashflow From Operations | -18.4% | -3,100 | -2,617 | -2,331 | -2,836 | -2,983 | -3,067 | -1,571 | -1,037 | -394 | -1,248 | -1,506 | - | - |
Share Based Compensation | 114.7% | 1,513 | 705 | 1,065 | 1,265 | 2,171 | 3,041 | 1,047 | 149 | 181 | 225 | 272 | - | - |
Cashflow From Financing | -100.2% | -15.28 | 6,175 | 415 | 1,920 | 5,068 | -594 | 7,126 | - | - | -106 | -60.78 | - | - |
CONDENSED STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses | ||
General and administrative | $ 3,297,350 | $ 3,814,184 |
Research and development | 392,813 | 222,491 |
Total operating expenses | 3,690,163 | 4,036,675 |
Loss from operations | (3,690,163) | (4,036,675) |
Other income (expense) | ||
Interest expense | (3,928) | |
Loss on extinguishment of debt | (36,850) | |
Change in fair value of notes | 335,364 | |
Other expense | (3,022) | (91,658) |
Total other income (expense) | (3,022) | 202,928 |
Net loss | $ (3,693,185) | $ (3,833,747) |
Basic weighted average number of shares outstanding | 7,418,281 | 743,373 |
Diluted weighted average number of shares outstanding | 7,418,281 | 743,373 |
Basic net loss per share | $ (0.50) | $ (5.16) |
Diluted net loss per share | $ (0.50) | $ (5.16) |
CONDENSED BALANCE SHEETS - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash | $ 1,626,892 | $ 4,710,642 |
Prepaid and other current assets | 1,266,211 | 969,763 |
Total current assets | 2,893,103 | 5,680,405 |
Total assets | 2,893,103 | 5,680,405 |
Current liabilities | ||
Accrued expenses | 65,128 | 177,118 |
Accrued expenses - compensation | 787,981 | |
Total current liabilities | 1,203,095 | 1,795,332 |
Deferred revenue | 500,000 | 500,000 |
Total liabilities | 1,703,095 | 2,295,332 |
Commitments and contingencies (Note 8) | ||
Stockholders' Equity (Deficit) | ||
Common stock, par value $0.0001; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 7,465,629 and 7,401,242 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 747 | 740 |
Additional paid-in capital | 56,912,182 | 55,414,069 |
Accumulated deficit | (55,722,926) | (52,029,741) |
Total stockholders' equity (deficit) | 1,190,008 | 3,385,073 |
Total liabilities, and stockholders' equity (deficit) | 2,893,103 | 5,680,405 |
Series X Preferred Stock | ||
Stockholders' Equity (Deficit) | ||
Preferred stock, par value $0.0001, 10,000,000 shares authorized: Series X preferred shares, 500,000 shares authorized as of March 31, 2024 and December 31, 2023; 45,567 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 5 | 5 |
Excludes related party | ||
Current liabilities | ||
Accounts payable | $ 1,137,967 | 811,733 |
Related party | ||
Current liabilities | ||
Accounts payable | $ 18,500 |